Difference between revisions of "Team:Nottingham/Model"
| Line 2: | Line 2: | ||
{{Template:Nottingham/menu}} | {{Template:Nottingham/menu}} | ||
<html> | <html> | ||
| − | + | <script src="https://2015.igem.org/common/MathJax-2.5-latest/MathJax.js?config=AM_CHTML"> | |
<section class="sidebar-content"> | <section class="sidebar-content"> | ||
<div class="main appear"> | <div class="main appear"> | ||
| Line 40: | Line 40: | ||
</div> | </div> | ||
<p>The main analytical result of our modelling work was the derivation of a condition that determines whether effective temperate phage therapy treatment can occur when prophage induction is allowed:</p> | <p>The main analytical result of our modelling work was the derivation of a condition that determines whether effective temperate phage therapy treatment can occur when prophage induction is allowed:</p> | ||
| − | <p> | + | <p>`\[\frac{(b-1)k_a}{d_P}>\frac{u}{c(u-q_0-d_X)}.\]`</p> |
<p>Our estimated parameters satisfy this inequality so provided our antisense RNA and dCas9 contructs are effective at suppressing toxin production in lysogens this should lead to a stable population of non-toxigenic <em>C. difficile</em> and SBRC phage which would help to prevent reinfection. We also noticed with our induction model that initial phage dose is less crucial to effective treatment. This is particularly important since we gathered from Dr Cath Rees that high phage titre, are difficult to produce and would lead to a costly therapy. Therefore, the ability of our phage to be effective at a low initial dose should lead to a more affordable treatment. From these results we decided to allow SBRC phage to undergo prophage induction at its natural rate instead of preventing induction as we had initially planned.</p> | <p>Our estimated parameters satisfy this inequality so provided our antisense RNA and dCas9 contructs are effective at suppressing toxin production in lysogens this should lead to a stable population of non-toxigenic <em>C. difficile</em> and SBRC phage which would help to prevent reinfection. We also noticed with our induction model that initial phage dose is less crucial to effective treatment. This is particularly important since we gathered from Dr Cath Rees that high phage titre, are difficult to produce and would lead to a costly therapy. Therefore, the ability of our phage to be effective at a low initial dose should lead to a more affordable treatment. From these results we decided to allow SBRC phage to undergo prophage induction at its natural rate instead of preventing induction as we had initially planned.</p> | ||
</div> | </div> | ||
Revision as of 16:45, 17 October 2018